A detailed history of Voya Investment Management LLC transactions in Replimune Group, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 111,957 shares of REPL stock, worth $1.67 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
111,957
Previous 76,098 47.12%
Holding current value
$1.67 Million
Previous $684,000 79.39%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.09 - $11.23 $290,099 - $402,696
35,859 Added 47.12%
111,957 $1.23 Million
Q2 2024

Aug 14, 2024

BUY
$5.01 - $9.46 $297,478 - $561,706
59,377 Added 355.1%
76,098 $684,000
Q1 2024

May 15, 2024

SELL
$6.87 - $9.31 $17,662 - $23,936
-2,571 Reduced 13.33%
16,721 $136,000
Q4 2023

Feb 14, 2024

BUY
$6.75 - $16.18 $16,773 - $40,207
2,485 Added 14.79%
19,292 $162,000
Q3 2023

Nov 14, 2023

BUY
$15.96 - $22.18 $4,612 - $6,410
289 Added 1.75%
16,807 $287,000
Q2 2023

Aug 14, 2023

SELL
$15.65 - $24.1 $2,582 - $3,976
-165 Reduced 0.99%
16,518 $383,000
Q1 2023

May 15, 2023

BUY
$17.48 - $29.09 $32,495 - $54,078
1,859 Added 12.54%
16,683 $294,000
Q3 2022

Nov 14, 2022

BUY
$15.6 - $21.15 $51,012 - $69,160
3,270 Added 28.3%
14,824 $256,000
Q4 2021

Feb 14, 2022

BUY
$25.43 - $34.25 $12,282 - $16,542
483 Added 4.36%
11,554 $313,000
Q3 2021

Nov 15, 2021

BUY
$28.98 - $39.54 $17,011 - $23,209
587 Added 5.6%
11,071 $328,000
Q2 2021

Aug 16, 2021

SELL
$28.5 - $39.37 $10,317 - $14,251
-362 Reduced 3.34%
10,484 $403,000
Q1 2021

May 17, 2021

BUY
$30.22 - $45.57 $25,898 - $39,053
857 Added 8.58%
10,846 $331,000
Q4 2020

Feb 16, 2021

BUY
$23.5 - $52.65 $234,741 - $525,920
9,989 New
9,989 $381,000

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $736M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.